<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

DU 145

Description

DU 145 (Prostate Cancer CDX Model) 

The DU 145 prostate cancer cell line was derived from a brain metastasis of prostate carcinoma. It is androgen-independent, providing a model for advanced and treatment-resistant disease. DU 145 has been widely applied in prostate cancer drug discovery. Its metastatic origin makes it valuable for translational research in late-stage cancer. 

Key Features: 

  • Derived from prostate carcinoma brain metastasis. 
  • Androgen-independent prostate cancer model. 
  • Expresses low levels of PSA. 
  • Consistent tumor formation in xenografts. 

Applications: 
DU 145 is applied in studies of castration-resistant prostate cancer biology. It supports evaluation of novel therapeutics beyond androgen receptor targeting. Researchers use it to investigate resistance pathways in advanced disease. Its metastatic origin provides relevance for late-stage prostate cancer research.

Details
Tumor Type
Prostate
Tumor Subtype
Prostate Prostate Carcinoma (derived from brain)
Organism
Human
Mouse Sex
Male
Mouse Strain
NOG
Mutated Genes
MLH1
Effect: Splice Acceptor Variant
Impact: Likely Pathogenic & Pathogenic
NF2
Mutation: p.E394del
Effect: Inframe Deletion
NOTCH2
Mutation: p.A1083SfsTer17
Effect: Frameshift Variant
Impact: Pathogenic
RET
Mutation: p.V804M
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic & Pathogenic / Likely Pathogenic
STK11
Mutation: p.K178GfsTer86
Effect: Frameshift Variant
TP53
Mutation: p.P223L
Effect: Missense Variant
Impact: Uncertain Significance
Mutation: p.V274F
Effect: Missense Variant
Impact: Pathogenic & Uncertain Significance & Likely Pathogenic
Lumin Data
RNASeq WES
Expression Data
Growth Curve
View on Lumin